The Biostatistics core of the proposed Johns Hopkins SPORE in lung cancer will consist of experienced faculty and of the Division of Biostatistics and Research Information Technology in the JHU Oncology Center, augmented by a faculty-level long term statistical collaborator of Dr. Belinsky in Colorado. A long history of collaboration already exists between the Oncology Biostatistics personnel and investigators on this SPORE. Its purpose is to: 1) Provide biostatistical consultation and support to all projects in the program, by assisting in the design, conduct, monitoring, visualization, analysis, quantitative modeling, interpretation and publication of the data arising in the course of program activities. 2) Provide the infrastructural support, systems programming, and computer expertise necessary for biostatistical activities within the program. 3) Improve the current clinical research database infrastructure of the lung cancer program at Johns Hopkins. Such support includes designing new interfaces for data entry, data retrieval, patient and sample tracking, interface with other electronic data systems, procedures to ensure data quality, integrity, confidentiality and establishing CaBIG compatibility to facilitate inter-project and inter-SPORE collaborations. The Core will have an integral role in the scientific development, execution, and analysis of all projects in the SPORE. Core investigators have extensive and complementary experiences in quantitative methods for biomedical applications, including both clinical and basic science studies. They take a direct interest in the substantive issues being investigated;to participating in regular project and program meetings, and to providing rigorous and innovative input on all quantitative matters arising in the projects. By contributing to multiple projects, they will also be in a position to promote interdisciplinary interactions among projects. This resource will also provide any needed bioinformatics consultation to projects in the program if they should arise, because a strong resource exists within the biostatistics program by virtue of its role in other SPORE programs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Kim, Jung-Hyun; Thimmulappa, Rajesh K; Kumar, Vineet et al. (2014) NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation. J Clin Invest 124:730-41
Ahuja, Nita; Easwaran, Hariharan; Baylin, Stephen B (2014) Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest 124:56-63
Izumchenko, Evgeny; Chang, Xiaofei; Michailidi, Christina et al. (2014) The TGF?-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res 74:3995-4005
Li, Huili; Chiappinelli, Katherine B; Guzzetta, Angela A et al. (2014) Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5:587-98
Wrangle, John; Machida, Emi Ota; Danilova, Ludmila et al. (2014) Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer. Clin Cancer Res 20:1856-64
Wrangle, John; Wang, Wei; Koch, Alexander et al. (2013) Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget 4:2067-79
Singh, Anju; Happel, Christine; Manna, Soumen K et al. (2013) Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest 123:2921-34
Rudin, Charles M; Brahmer, Julie R; Juergens, Rosalyn A et al. (2013) Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac Oncol 8:619-23
Reed, M D; Tellez, C S; Grimes, M J et al. (2013) Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Br J Cancer 109:1775-81
Kim, James; Aftab, Blake T; Tang, Jean Y et al. (2013) Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 23:23-34

Showing the most recent 10 out of 231 publications